EU approval for AirFluSal Forspiro generic competitor to Advair/Seretide for Asthma + COPD-Sandoz

Sandoz, has received Danish marketing authorisation for AirFluSal Forspiro (formerly known as VR315), an innovative new inhaler for patients with Asthma and Chronic Obstructive Pulmonary Disease (COPD). The Danish approval follows the completion of the EU regulatory process for eight EU countries. Denmark has approved both mid and high-strength dosage forms (50-250�g and 50-500�g) for the continuous treatment of patients above 12 years of age with persistent asthma or for symptomatic treatment of COPD in the same patient group. The Danish approval for the combo follows the completion of European decentralised procedures for seven additional countries.

This is the same combination of LABA salmeterol and the inhaled corticosteroid fluticasone as found in $7.7 billion sales, Advair/Seretide from Glaxo Smith Kline.